Document is current
Any future updates will be listed below
-
Authors
Wiseman, Marni https://orcid.org/0000-0001-9634-3750
Benvenuto, Marco
Strømkjær, Liv https://orcid.org/0009-0006-7424-7403
Paludan-Müller, Asger https://orcid.org/0000-0002-3364-1539
Ryttig, Lasse
Petersen, Anne Sohrt https://orcid.org/0000-0001-7286-5239
Wollenberg, Andreas https://orcid.org/0000-0003-0177-8722
-
Funding
Funding for this research was provided by:
LEO Pharma
- License Information
-
More Information
Article History
Received: 22 April 2025
Accepted: 29 September 2025
First Online: 16 October 2025
Declarations
:
: Liv Strømkjær and Asger Paludan-Müller are full-time employees of NHTA, a consultancy which performs market access consulting for pharmaceutical companies. Anne Sohrt Petersen is a former employee of LEO Pharma A/S, employed at Novo Nordisk A/S. Lasse Ryttig is a former employee of LEO Pharma A/S, employed at Zealand Pharma A/S. Marni Wiseman is a consultant for LEO Pharma A/S and a clinical investigator. Andreas Wollenberg has served as an advisor or paid speaker for, or participated in clinical trials (with honoraria paid to the institution) sponsored by: AbbVie, Aileens, Almirall, Amgen, Beiersdorf, Bioderma, Bioproject, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Chugai, DKSH, Eli Lilly, Galapagos, Galderma, Glenmark, GSK, Hans Karrer, Hexal, Janssen-Cilag, Kyowa Kirin, LEO Pharma, L’Oreal, Maruho, MedImmune, MSD, Mylan, MSD, Novartis, Pfizer, Pierre Fabre, Regeneron, Sandoz, Santen, Sanofi-Aventis and UCB. Marco Benvenuto has nothing to disclose.
: Ethical approval was not required for this study because the analysis is based on previously published research and cost inputs and does not contain data from any new studies with human participants or animals.
